USTR Opens §301 Investigation into Germany's Pharmaceutical Underpayment Practices

USTR Jamieson Greer initiated a §301 investigation on June 18, 2026, to determine whether Germany's persistent underpayment for innovative pharmaceutical products constitutes an unreasonable or discriminatory practice burdening U.S. commerce. The action follows months of bilateral discussions that failed to resolve the pricing dispute.